The Employees’ State Insurance Corporation (ESIC) has issued an important notification regarding a batch of a drug that has failed quality testing. Medical units under ESIC have been directed to immediately stop the use of the affected drug batch and initiate recovery and corrective actions.
📌 Details of the NSQ Drug Batch:
| Parameter | Details |
|---|---|
| Drug Name | Amoxycillin + Clavulanate + Lactic Acid Bacillus |
| Brand Name | Augpen LB 625 |
| Manufacturer | M/s Zuventus Healthcare Ltd. |
| Batch Number | Z05AF24052 |
| Date of Manufacture | 08/2024 |
| Expiry Date | 01/2026 |
| Reported by | ESIC Model Hospital, Baddi, H.P. |
| Testing Laboratory | Government Drug Lab, Distt. Solan, H.P. |
| Report Number & Date | 26-0887 dated 13.05.2025 |
| Issue Found | Non-compliance in assay of Amoxycillin |
🚨 Instructions Issued to Medical Units:
Stop Usage: All user units must immediately stop using the specified batch.
Recovery from Firm: Initiate recovery of the cost of materials and testing charges (if any) from the supplier.
Tender Action: Act as per relevant clauses under DG-ESIC Tender Enquiry/Rate Contract regarding drug quality.
Documentation: Maintain a record of all actions taken.
This action ensures patient safety and reinforces ESIC’s commitment to stringent drug quality control.
